Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia.
Earle E BainLaura ShafnerDavid P WallingAhmed A OthmanChristy Chuang-SteinJohn HinkleAdam HaninaPublished in: JMIR mHealth and uHealth (2017)
ClinicalTrials.gov NCT01655680 https://clinicaltrials.gov/ct2/show/NCT01655680?term=NCT01655680.